CAR T-cell and vaccine treatment after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 study tests a customized immune-cell treatment (CAR T-cells) plus a vaccine given after stem cell transplant for certain aggressive B-cell non-Hodgkin lymphomas. It aims to help your immune system better recognize and attack the lymphoma and to see how safe the approach is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and can give consent (or your legal representative can).
- Your lymphoma is an intermediate- or high-grade B-cell type and you either relapsed after first remission or did not fully respond to first treatment.
- You’ve not had a prior stem cell transplant (either your own or someone else’s).
- You test positive for CMV (a common virus that many people have had before).
- You can safely undergo transplant and study procedures (good heart/lung function and adequate blood counts).
- You must not currently have certain infections or immune conditions (including HIV, active hepatitis, or uncontrolled infections).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests genetically modified immune cells (made from your own blood) plus a vaccine aimed at controlling CMV-related lymphoma. It’s for adults with intermediate or high-grade B-cell non-Hodgkin lymphoma who can’t get (or don’t want) certain standard stem-cell transplant options.
This Phase 1/2 study tests a customized type of immune cell treatment (CD19 CAR T-cells) for people with certain relapsed or hard-to-treat lymphomas or CLL/SLL. It aims to improve control of disease by targeting the CD19 marker on cancer cells.
This trial studies a type of lab-made immune cell therapy (CAR T) using cells called CAR-20/19-T. It is for adults with relapsed or refractory B-cell cancers, aiming to reduce or eliminate lymphoma in people whose disease has come back or not responded to standard treatments.
This trial tests a combination treatment: a stem cell transplant followed by CAR-T cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. It is for those with high-risk features like large tumors or certain genetic changes.
This Phase 1 study tests a new immune-cell treatment made from donated cord blood. It aims to treat people whose B-cell lymphoma has come back or did not respond, specifically when the tumor has CD19 on it.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
Hear when a new B-Cell Non-Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.